Tag archive for ‘BreathID’
Jewish Business News On Wednesday, May 6th, 2015

Exalenz Bioscience Launches Study of Breath-Based Diagnostic Test Addressing the $2 Billion NASH Market Potential

– – Israel’s Exalenz Bioscience (TASE: EXEN), a developer and marketer of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, announced More...

Globes On Saturday, July 27th, 2013

Exalenz Bioscience raises NIS 28 million ($ 7.7 million) in rights issue

– The company has developed the BreathID device for diagnosis diseases of the digestive tract from a patient’s breath. – / By Gali Weinreb / Exalenz Bioscience Ltd. (TASE:EXEN) completed on More...

Wordpress site Developed by Fixing WordPress Problems